Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | TPSAB1 | Q15661 | 6/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006377 | 0.83 | CYP2C9 (0.42) | CYP2C9CYP2C19TPSAB1PRSS1KMT2A | |
| SCHEMBL6563716 | 0.83 | CYP2C9 (0.59) | CYP2C9CYP2C19RECQLCA1CA2 | |
| SCHEMBL3497836 | 0.81 | KMT2A (0.59) | KMT2APOLB | |
| SCHEMBL626651 | 0.78 | TPSAB1 (0.70) | CYP2C9CYP2C19RECQLTPSAB1PRSS1 | |
| SCHEMBL27589884 | 0.78 | CYP2C9 (0.68) | CYP2C9CYP2C19RECQLTPSAB1PRSS1 | |
| SCHEMBL8245710 | 0.78 | CYP2C9 (0.68) | CYP2C9CYP2C19RECQLTPSAB1PRSS1 | |
| SCHEMBL8139643 | 0.78 | CYP2C9 (0.68) | CYP2C9CYP2C19RECQLTPSAB1PRSS1 | |
| SCHEMBL27288503 | 0.76 | EPHX2 (0.64) | KMT2AMEN1CA1CA2EPHX2 | |
| SCHEMBL22466338 | 0.76 | CYP2C9 (0.66) | CYP2C9CYP2C19RECQLTPSAB1PRSS1 | |
| SCHEMBL20715702 | 0.76 | CYP2C9 (0.66) | CYP2C9CYP2C19RECQLTPSAB1PRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2450374-B9 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2016-11-23 | — | — | EP | disclosed |
| US-9260500-B2 | Peptide and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-02-16 | — | — | US | disclosed |
| EP-2450374-B1 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-09-30 | — | — | EP | disclosed |
| US-20120172293-A1 | PEPTIDE AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2012-07-05 | — | — | US | disclosed |
| EP-2450374-A1 | PEPTIDE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172293-A1 | PEPTIDE AND USE THEREOF | GLP1R, GIPR, SCTR | CYP2C9 3076/4885CYP2C19 1536/4885RECQL 4369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.